Abstract

Recent successes in developing small molecule degraders that act through the ubiquitin system have spurred efforts to extend this technology to other mechanisms, including the autophagosomal-lysosomal pathway. Therefore, reports of autophagosome tethering compounds (ATTECs) have received considerable attention from the drug development community. ATTECs are based on the recruitment of targets to LC3/GABARAP, a family of ubiquitin-like proteins that presumably bind to the autophagosome membrane and tether cargo-loaded autophagy receptors into the autophagosome. In this work, we rigorously tested the target engagement of the reported ATTECs to validate the existing LC3/GABARAP ligands. Surprisingly, we were unable to detect interaction with their designated target LC3 using a diversity of biophysical methods. Intrigued by the idea of developing ATTECs, we evaluated the ligandability of LC3/GABARAP by in silico docking and large-scale crystallographic fragment screening. Data based on approximately 1000 crystal structures revealed that most fragments bound to the HP2 but not to the HP1 pocket within the LIR docking site, suggesting a favorable ligandability of HP2. Through this study, we identified diverse validated LC3/GABARAP ligands and fragments as starting points for chemical probe and ATTEC development.

Autophagosome tethering compounds (ATTECs) are small molecule degraders hijacking the autophagy system. Here, the authors show that current ATTEC ligands did not bind to their designated targets but establish good ligandability of ATG8 isoforms through fragment screening and docking.

Details

Title
Critical assessment of LC3/GABARAP ligands used for degrader development and ligandability of LC3/GABARAP binding pockets
Author
Schwalm, Martin P. 1   VIAFID ORCID Logo  ; Dopfer, Johannes 2   VIAFID ORCID Logo  ; Kumar, Adarsh 2   VIAFID ORCID Logo  ; Greco, Francesco A. 2   VIAFID ORCID Logo  ; Bauer, Nicolas 2   VIAFID ORCID Logo  ; Löhr, Frank 3   VIAFID ORCID Logo  ; Heering, Jan 4   VIAFID ORCID Logo  ; Cano-Franco, Sara 5   VIAFID ORCID Logo  ; Lechner, Severin 6   VIAFID ORCID Logo  ; Hanke, Thomas 2   VIAFID ORCID Logo  ; Jaser, Ivana 7   VIAFID ORCID Logo  ; Morasch, Viktoria 2   VIAFID ORCID Logo  ; Lenz, Christopher 2   VIAFID ORCID Logo  ; Fearon, Daren 8   VIAFID ORCID Logo  ; Marples, Peter G. 8   VIAFID ORCID Logo  ; Tomlinson, Charles W. E. 8   VIAFID ORCID Logo  ; Brunello, Lorene 5   VIAFID ORCID Logo  ; Saxena, Krishna 2   VIAFID ORCID Logo  ; Adams, Nathan B. P. 7   VIAFID ORCID Logo  ; von Delft, Frank 8   VIAFID ORCID Logo  ; Müller, Susanne 2   VIAFID ORCID Logo  ; Stolz, Alexandra 5   VIAFID ORCID Logo  ; Proschak, Ewgenij 9   VIAFID ORCID Logo  ; Kuster, Bernhard 6   VIAFID ORCID Logo  ; Knapp, Stefan 1   VIAFID ORCID Logo  ; Rogov, Vladimir V. 2   VIAFID ORCID Logo 

 Goethe University Frankfurt, Institute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); Goethe University Frankfurt, Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); DKTK site Frankfurt-Mainz, German Cancer Consortium (DKTK) / German Cancer Research Center (DKFZ), Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584) 
 Goethe University Frankfurt, Institute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); Goethe University Frankfurt, Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721) 
 Goethe University Frankfurt, Institute for Biophysical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721) 
 Theodor-Stern-Kai 7, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany (GRID:grid.510864.e) 
 Goethe University, Institute of Biochemistry II (IBC2), Faculty of Medicine, Frankfurt am Main, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); Goethe University, Buchmann Institute for Molecular Life Sciences (BMLS), Frankfurt am Main, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721) 
 Technical University of Munich, Chair of Proteomics and Bioanalytics, TUM School of Life Sciences, Freising, Germany (GRID:grid.6936.a) (ISNI:0000 0001 2322 2966) 
 NanoTemper Technologies GmbH, Munich, Germany (GRID:grid.511332.7) (ISNI:0000 0004 4659 2945) 
 Harwell Science and Innovation Campus, Diamond Light Source Ltd., Didcot, UK (GRID:grid.18785.33) (ISNI:0000 0004 1764 0696) 
 Goethe University Frankfurt, Institute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); Theodor-Stern-Kai 7, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany (GRID:grid.510864.e) 
Pages
10204
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3132705766
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.